Burbank, CA, December 08, 2015 --(PR.com
)-- Imaging3™, Inc. (OTCBB: IMGGQ) announced today that it has appointed Dr. Arthur Lu as a director of the company.
Dr. Arthur Lu, age 61, has been a director of the Company since December 1, 2015. Since 1987, Dr. Lu has worked in private practice as an ophthalmologist. He worked as an ophthalmologist at Magnolia Eye Care, Medical Center, Inc. from 1987 to 2005. Dr. Lu has been an assistant clinical professor at the University of California, San Diego from 1987 to 1997. He is a member of the American Academy of Ophthalmology, California Medical Association, and Orange County Medical Association. Dr. Lu became a fellow of the American Board of Ophthalmology in 1989, a diplomat of the American Board of Ophthalmology in 1988, a licensed physician and surgeon in California in 1985, and a diplomat of the National Board of Medical Examiners in 1984. Dr. Lu received his Doctor of Medicine from the University of California, Irvine in 1983, his Master of Science degree in electrical engineering from the University of Southern California in 1978, his Bachelor of Science degree in electrical engineering from California State University at Los Angeles in 1976, and his Bachelor of Science degree in biochemistry from California State University at Los Angeles in 1974.
Dane Medley, President and CEO of Imaging3, stated, “We are very pleased to welcome Dr. Lu to the Imaging3 board. We value what he has to bring to the company and are looking forward to the future.”
Imaging3, Inc., founded in 1993, has developed a medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com for more information
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, failure to obtain a trading symbol from FINRA, failure to consummate desired business combinations or transactions, delays or adverse rulings relating to its pending Chapter 11 bankruptcy action, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction, potential product liability claims, and other factors detailed in reports filed by the Company. Imaging3 cannot assure that it will obtain regulatory approval for the Dominion VI Scanner or any other products, successfully complete the Chapter 11 bankruptcy process, successfully complete its financial statements, or obtain a trading symbol from FINRA.